Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies.
Autor: | Yang R; a Protein Analytics, Adimab , Lebanon , NH , USA., Jain T; b Computational Biology, Adimab , Palo Alto , CA , USA., Lynaugh H; a Protein Analytics, Adimab , Lebanon , NH , USA., Nobrega RP; a Protein Analytics, Adimab , Lebanon , NH , USA., Lu X; a Protein Analytics, Adimab , Lebanon , NH , USA., Boland T; b Computational Biology, Adimab , Palo Alto , CA , USA., Burnina I; a Protein Analytics, Adimab , Lebanon , NH , USA., Sun T; a Protein Analytics, Adimab , Lebanon , NH , USA., Caffry I; a Protein Analytics, Adimab , Lebanon , NH , USA., Brown M; a Protein Analytics, Adimab , Lebanon , NH , USA., Zhi X; a Protein Analytics, Adimab , Lebanon , NH , USA., Lilov A; a Protein Analytics, Adimab , Lebanon , NH , USA., Xu Y; a Protein Analytics, Adimab , Lebanon , NH , USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | MAbs [MAbs] 2017 May/Jun; Vol. 9 (4), pp. 646-653. Date of Electronic Publication: 2017 Feb 14. |
DOI: | 10.1080/19420862.2017.1290753 |
Abstrakt: | Susceptibility of methionine to oxidation is an important concern for chemical stability during the development of a monoclonal antibody (mAb) therapeutic. To minimize downstream risks, leading candidates are usually screened under forced oxidation conditions to identify oxidation-labile molecules. Here we report results of forced oxidation on a large set of in-house expressed and purified mAbs with variable region sequences corresponding to 121 clinical stage mAbs. These mAb samples were treated with 0.1% H |
Databáze: | MEDLINE |
Externí odkaz: |